News

Bayer and Atara Biotherapeutics Enter into Solid Tumor Treatment Agreement

December 07, 2020

The companies have entered into an agreement for next-generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.

Vivlion Signs Worldwide License Agreement for CRISPR/Cas9 Patent Portfolio

December 04, 2020

Startup company Vivlion has signed a non-exclusive license agreement with ERS Genomics granting access to CRISPR/Cas9 patent portfolio.

CGT Catapult Report Shows Industry Progress to Commercialization of Therapies

December 04, 2020

New data from CGT Catapult has demonstrated progression by the industry toward commercialization of therapies and an increase in GMP manufacturing space.

Raw Material Delays Cut Pfizer Vaccine Production

December 04, 2020

A longer-than-expected scale up of raw materials forces Pfizer to cut 2020 vaccine production in half.

Lonza Announces Long-Term Collaboration with Global Biopharma Company

December 04, 2020

Lonza has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation.

Honeywell Completes Remote Control System Migration for Hungarian Pharma Manufacturer

December 03, 2020

Honeywell’s project team has remotely and efficiently migrated Richter Gedeon’s process control system with limited onsite staffing and resources.

BioSkryb Discusses First Data Demonstrating Improved Accuracy in Single Cell Analyses

December 03, 2020

A novel PTA technology captures more than 95% of the genomes of single cells, providing more uniform, accurate, and reproducible single-cell analysis data.

Cytiva and 4Tune Engineering Collaborate on Cell Therapy Quality Risk Management

December 03, 2020

The collaboration addresses the need for risk mitigation plans in cell therapies.

J&J Initiates COVID-19 Vaccine Approvals in Canada and Europe

December 03, 2020

Janssen announces rolling submissions for its COVID-19 vaccine with Health Canada and EMA.

Janssen Pharmaceuticals Announces Acquisition of Vision Care Gene Therapy

December 03, 2020

The gene therapy increases the ability of retina cells to make a soluble form of CD59, a protein that shields the retina from damage, to prevent additional damage and to preserve vision.